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Abstract: The aim of this research was to increase the oral bioavailability of daidzein by the 
  formulations of poly(lactic-co-glycolic) acid (PLGA) nanoparticles loaded with daidzein. Amongst 
the various traditional and novel techniques of preparing daidzein-loaded PLGA nanoparticles, 
daidzein-loaded phospholipid complexes PLGA nanoparticles and daidzein-loaded cyclodextrin 
inclusion complexes PLGA nanoparticles were selected. The average drug entrapment efficiency, 
particle size, and zeta potential of daidzein-loaded phospholipid complexes PLGA nanoparticles 
and daidzein-loaded cyclodextrin inclusion complexes PLGA nanoparticles were 81.9% ± 5%, 
309.2 ± 14.0 nm, −32.14 ± 2.53 mV and 83.2% ± 7.2%, 323.2 ± 4.8 nm, −18.73 ± 1.68 mV , 
respectively. The morphological characterization of nanoparticles was observed with scanning 
electron microscopy by stereological method and the physicochemical state of nanoparticles was 
valued by differential scanning calorimetry. The in vitro drug-release profile of both nanoparticle 
formulations fitted the Weibull dynamic equation. Pharmacokinetic studies demonstrated that 
after oral administration of daidzein-loaded phospholipid complexes PLGA nanoparticles and 
daidzein-loaded cyclodextrin inclusion complexes PLGA nanoparticles to rats at a dose of 
10 mg/kg, relative bioavailability was enhanced about 5.57- and 8.85-fold, respectively, compared 
to daidzein suspension as control. These results describe an effective strategy for oral delivery 
of daidzein-loaded PLGA nanoparticles and might provide a fresh approach to enhancing the 
bioavailability of drugs with poor lipophilic and poor hydrophilic properties.
Keywords: daidzein, phospholipid complexes, cyclodextrin inclusion complexes, PLGA, 
nanoparticles
Introduction
Daidzein (4′,7-dihydroxylisoflavone) is a water-insoluble isoflavone,1 isolated mainly 
from leguminous plants, which is used in the treatment of hypertension, coronary 
heart disease, cerebral thrombosis, and menopause syndrome. Recently, studies 
demonstrated that daidzein could inhibit the growth of cancer cells by activating a 
cell death pathway and prevent the onset of diabetes.2–4 Thus, daidzein is a promising 
multipurpose treatment. However, the oral bioavailability of daidzein is very poor, 
which limits its curative effect.5–8 Animal experiments also showed that the absolute 
bioavailability of daidzein suspension after oral administration to rats was only 6.1%.6 
There is a consensus that the low bioavailability of daidzein is related to the drug’s 
physicochemical properties which include low solubility, low partition coefficient of 
oil/water, and, in particular, strong metabolism that occurs in the intestine and liver.9 
Many microparticulate systems have been used in an attempt to address this issue, 
such as self-microemulsion and solid lipid nanoparticles drug delivery systems, and 
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have demonstrated that bioavailability of daidzein increased 
by 2.5-, 2.9-, and 6.9-fold.10–13 An oral route of administration 
– attractive due to its convenience, patient acceptance, 
and cost-effectiveness, particularly in the case of chronic 
therapies – was developed.14 In recent years, nano-based 
drug delivery systems, such as polymeric nanoparticles, 
have demonstrated obvious advantages in improving the 
oral bioavailability and pharmacological activities of poorly 
soluble drugs;15 in particular, nanoparticles of synthetic 
polyester such as poly(lactic-co-glycolic) acid (PLGA) 
is often chosen due to its biocompatibility and versatility 
in encapsulating a variety of drugs.16–18 Oral delivery of 
PLGA nanoparticles has also been well studied.19 Some 
of the commonly reported methods of preparing PLGA 
nanoparticles include emulsification-solvent evaporation and 
double-emulsification, which represent easy and reproducible 
techniques that have been widely used by several research 
groups to prepare nanoparticles.20 However, the incorporation 
of daidzein into polymeric-based nanocarriers may be 
greatly restricted by these methods due to poor lipophilicity 
and poor hydrophilicity. To overcome these kinds of issues, 
efforts have been made to increase affinity for hydrophobic 
carrier materials of poor lipophilicity drugs.11,21 Additionally, 
cyclodextrins, well-known cyclic oligosaccharides with a 
lipophilic central cavity and a hydrophilic outer surface, 
are able to form inclusion complexes with insoluble 
molecules like camptothecin.22 Therefore, by improving the 
  liposolubility and solubility of daidzein with these techniques 
combined with the benefits of PLGA nanoparticles, it may be 
feasible to increase the oral bioavailability of daidzein.
Based on previous information, the aim of this work 
was, firstly, to separately prepare daidzein phospholipid 
complexes and daidzein cyclodextrin inclusion complexes 
and encapsulate into PLGA nanoparticles. Secondly, the 
physicochemical characteristics of nanoparticles were 
evaluated. Scanning electron microscopy (SEM) was used 
to characterize particle morphology, while the physical 
status of daidzein inside the nanoparticles was investigated 
by differential scanning calorimetry. Finally, an in vitro 
release test was used to analyze drug release behavior, and 
blood concentration was measured after oral administration 
to rats to measure the bioavailability of daidzein. This study 
concluded that PLGA combined with phospholipid or cyclo-
dextrin as a carrier material could be applied to water soluble 
and poorly water soluble compounds, respectively, to control 
drug release. This is the first report which couples these two 
formulations with daidzein to improve its oral bioavailability 
and suggests that this innovative strategy could be effective 
in improving the oral absorption of poor hydrophilic and 
poor lipophilic drugs.
Materials
Daidzein (purity .98%) was obtained from Qingze Medical 
Technology Development Co Ltd (Nanjing, China). PLGA 
(lactic:glycolic 50:50, molecular weight [Mw] 15,000 Da), 
phosphatidylcholine, hydroxypropyl-beta-cyclodextrin 
(Mw 1400 Da), acetonitrile, methylene chloride, chloroform, 
and dimethyl sulfoxide were purchased from Sinopharm 
  Chemical Reagent Co Ltd (Shanghai, China). Polyvinyl 
alcohol (PVA, viscosity 11–14 cp) was obtained from 
Kayon Biological Technology Co Ltd (Shanghai, China). 
Distilled water was produced by a Milli-Q® purification 
system (Millipore Corporation, Billerica, MA). The rest of 
the chemicals and reagents used were of analytical grade.
Methods
Solubility studies
Before the preparation of daidzein-loaded nanoparticles, the 
solubilization process of daidzein was studied. Briefly, an 
excess amount of daidzein was added into 1 mL of water, 
methylene chloride, chloroform, or 2% PVA aqueous   solution 
in a centrifugal tube. Daidzein-phospholipid complexes were 
added into 1 mL of methylene chloride or chloroform and a 
certain amount of daidzein-cyclodextrin inclusion complexes 
were added into 1 mL of water or 2% PVA aqueous solution. 
These samples were shaken reciprocally at 25°C for 48 hours. 
This preexperiment showed that daidzein could reach 
solubility equilibrium and keep stability in 48 hours. After 
this period of time, the suspensions were filtered through a 
0.45 µm membrane filter (Millipore) in order to remove the 
undissolved daidzein. The concentration of daidzein in the 
filtrate was measured by high performance liquid chroma-
tography (HPLC) after appropriate dilution with methanol. 
The solubility experiments were conducted in triplicate and 
no interferences in the analysis of daidzein from the pres-
ence of both phosphatidylcholine and hydroxypropyl-beta-
cyclodextrin were found.
Preparation of daidzein complexes
Daidzein-phospholipid complexes preparation
A schematic diagram of the formation of daidzein-loaded 
phospholipid complexes PLGA nanoparticles (D-PNPs) and 
daidzein-loaded cyclodextrin inclusion complexes PLGA 
nanoparticles (D-CNPs) is shown in Figure 1. As described in 
Figure 1A, daidzein-phospholipid complexes were prepared 
according to a previous report in which insulin-phospholipid 
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complexes were constructed.23 In brief, daidzein (2 mg) was 
added to 5 mL ethanol, containing 20 mg phosphatidylcho-
line, in a water bath at 40°C. After stirring for 12 hours, 
ethanol was removed by nitrogen gas and the residues were 
collected to obtain the daidzein-phospholipid complexes.
Daidzein-cyclodextrin inclusion complexes 
preparation
Daidzein-cyclodextrin inclusion complexes were prepared 
by a fluid inclusion method,22 which is shown in Figure 1B. 
Briefly, daidzein was added to 5 mL methanol, containing 
1:10 molar ratio of hydroxypropyl-beta-cyclodextrin, at 
30°C. After stirring for 12 hours, methanol was volatilized 
by nitrogen gas and the residues were collected.
Preparation of nanoparticles
D-PNPs preparation
As shown in Figure 1A, D-PNPs were prepared by an 
emulsion-solvent evaporation method.23 Briefly, the obtained 
daidzein-phospholipid complexes were dissolved in 2 mL 
of methylene chloride containing 60 mg PLGA previously 
dissolved. The organic phase was emulsified in 20 mL of 
aqueous phase containing PVA (1%, weight/volume [w/v]) 
by sonication over an ice-bath using a Scientz-IID ultrasonic 
probe (LifeScientz Bio-technology Co, Ltd, Ningbo, China) at 
an output of 450 W for 5 minutes to form an oil-in-water (o/w) 
emulsion. Then, the organic solvent was evaporated under vac-
uum at a temperature of 30°C in a rotary evaporator (RE52CS; 
Xian Depai Biotechnology Co, Ltd, Shaanxi, China). The 
residues were solidified by the addition of sodium chloride 
aqueous solution (1%, w/v) at 0°C. After the nanosuspensions 
were centrifuged and washed three times with ultra-pure water, 
the formulations were frozen and freeze-dried (ALPHA 1–2/
LDplus; Martin Christ GmbH, Osterode am Harz, Germany) 
using trehalose (2%, weight/weight) as a cryoprotectant.
D-CNPs preparation
As shown in Figure 1B, D-CNPs were prepared by a double 
emulsion method.20 Briefly, 1.0 mL of PVA aqueous solu-
tion (2%, w/v) containing daidzein-cyclodextrin inclusion 
complexes was emulsified in 2 mL of chloroform, containing 
20 mg phosphatidylcholine and 60 mg PLGA, by high-speed 
homogenization at 10,000 rpm for 2 minutes. The primary 
emulsion was added to 20 mL of PVA solution (1%, w/v) and 
sonicated at 450 W for 5 minutes to form a double-emulsion. 
Organic solvent residues were removed and the following 
procedures were the same as described above.
hPLC analytical method
The amount of daidzein loaded into nanoparticles was eval-
uated by HPLC. Briefly, the chromatography system used 
was composed of a Shimadzu LC-20AT chromatographic 
system with an LC-20AT binary pump and an SPD-20A 
ultraviolet-visible detector (Shimadzu Corporation, Tokyo, 
Japan). Data processing was performed with LCsolution 
software (v1.0.0.1; Shimadzu). Analysis was carried out on 
a Dikma Dimonsil C18 column (200 mm × 4.6 mm, 5 µm; 
Dikma Technologies, Inc, Beijing China). The mobile phase 
was composed of methanol and deionized water (55:45 
volume/volume),9 and the flow rate was 1.0 mL/minute. 
Column temperature was maintained at 25°C, ultraviolet-
visible detection wavelength was set at 249 nm, and injec-
tion volume was 20 µL.
Characterization of nanoparticles
Particle size and zeta potential of nanoparticles were deter-
mined by a particle size analyzer (90Plus; Brookhaven 
Instruments Corporation, Holtsville, NY). Nanoparticle 
suspension was analyzed by autocorrelation to determine 
both mean size and zeta potential. All measurements were 
performed in triplicate.
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Figure 1 Schematic diagram of the formations of daidzein-loaded phospholipid complexes poly(lactic-co-glycolic) acid nanoparticles and daidzein-loaded cyclodextrin 
inclusion complexes poly(lactic-co-glycolic) acid nanoparticles.
Abbreviations: hP-β cyclodextrin, hydroxypropyl-beta-cyclodextrin; PLGA, poly(lactic-co-glycolic) acid.
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Morphological evaluation of the nanoparticles was 
performed using SEM (FEI™ Sirion 200/Inca Oxford; FEI 
Company, Hillsboro, OR). Briefly, a drop of the dilute nano-
particle suspension was placed onto a copper sheet and then 
dried under reduced pressure at 40°C. For SEM analysis, the 
surfaces of the corresponding membranes were covered with 
gold in a vacuum before viewing under the microscope.
Thermogram characteristics of selected batches of 
nanoparticles were determined by differential scanning 
calorimetry (Pyris 1; PerkinElmer, Waltham, MA). Samples 
(blank-PNPs, blank-CNPs, D-PNPs, D-CNPs, and pure 
daidzein as a control – calculated by drug loading which 
contained 2 mg daidzein) were placed separately in a 
series of sealed aluminum pans and detected. Samples 
were scanned at 200°C–400°C and heated at a rate of 
10°C/minute.24
Drug encapsulation efficiency and drug loading were 
analyzed by HPLC method. Briefly, 100 µL of evaporated 
nanoparticle suspension was sucked out and mixed with 
900 µL dimethyl sulfoxide to destruct the nanoparticles. 
After being vortexed for 30 seconds, 100 µL of sample 
was withdrawn and 900 µL of methanol was added to 
precipitate insoluble polymers. After the mixture was vor-
texed again and centrifuged, the supernatant was filtered 
using a 0.45 µm membrane filter (Millipore) and the result 
was calculated as Wtotal. Similarly, the amount of daidzein 
entrapped in the nanoparticles was determined by the fol-
lowing procedure: evaporated nanoparticle suspension 
(100 µL) was sucked out and centrifuged (12,000 rpm, 
30 minutes) in order to remove the nonentrapped daidzein. 
Then, 1 mL dimethyl sulfoxide was added to destruct the 
nanoparticles. After being vortexed for 30 seconds, 100 µL 
of sample was   withdrawn and 900 µL of methanol was 
added to precipitate insoluble polymers. After the mixture 
was vortexed again and centrifuged, the supernatant was 
filtered using a 0.45 µm membrane filter (Millipore) and the 
yield was calculated as Wentrapped.   Triplicate samples were 
prepared for each of the   formulations. Drug encapsulation 
efficiency (%) and drug loading (%) were calculated by the 
following equations:
  Encapsulation efficiency = (Wentrapped/Wtotal) × 100
  Drug loading = (Wentrapped/WNPs) × 100
where Wtotal was the total amount of daidzein, Wentrapped was 
the amount of encapsulated drug, and WNPs was the weight 
of the freeze-dried nanoparticles.
In vitro release study
The in vitro release study was carried out using the dialysis 
bag diffusion technique. The release rate of daidzein from 
the nanoparticles was measured by HPLC and performed in 
a thermo shaker bath system (HZ-9212S Shaking Incubator; 
Taicang Science & Technology Equipment Inc, Taicang, 
China). which was maintained at 37°C and shaken horizon-
tally at 100 rpm. Freeze-dried nanoparticles (calculated by 
drug loading which contained 1 mg daidzein and determined 
at the first time interval in the dissolution media by HPLC) 
or 1 mg pure daidzein was placed in a dialysis membrane 
bag with a molecular cut-off of 3500 Da (Shanghai Green-
Bird Science & Technology Development Co Ltd, Shanghai, 
China), all groups were in sink condition with this amount of 
drug. Then, each group of samples was immersed in 30 mL 
of phosphate buffer solution (pH 7.4). After a particular time 
interval (0, 1, 2, 4, 6, 12, 24, 36, 48, 60, and 72 hours), 1 mL 
of the dissolution medium was withdrawn and the nano-
particles were resuspended in medium which was replaced 
with equal volume of fresh dissolution medium at the same 
temperature. The released daidzein in the dissolution media 
was determined by HPLC. Measurements were performed 
in triplicate for each batch.
Bioavailability studies
In vivo pharmacokinetics study was carried out using male 
Sprague Dawley rats (250 ± 10 g). The animal experimental 
protocols were performed according to the guidelines of the 
Experimental Animal Ethics Committee of Shanghai Jiao 
Tong University (Shanghai, China). These healthy rats were 
randomly divided into three treatment groups and fasted 
overnight with free access to water before drug administra-
tion. They were administered orally with D-PNPs, D-CNPs, 
or daidzein suspension (daidzein dispersed in 0.5% sodium 
carboxymethyl cellulose solution) at a dose of 10 mg/kg. After 
administration, 300 µL blood samples were collected from the 
retroorbital plexus at predetermined time points of 0.5, 1, 1.5, 
2, 4, 8, 12, 24, 36, and 48 hours and placed into heparinized 
microcentrifuge tubes (100 IU/mL blood). The blood samples 
were centrifuged at 5000 rpm for 5 minutes and the separated 
plasma samples were stored at −80°C until analysis.
Daidzein concentration in plasma, with 0.5 µg/mL 
  ethylparaben as the internal standard, was determined 
by HPLC method. Plasma samples were prepared in the 
  following steps: 100 µL plasma was firstly mixed with 10 µL 
internal standard and then 900 µL acetonitrile was added to 
the plasma. Vortexed for 5 minutes, the plasma sample was 
centrifuged at 12,000 rpm for 10 minutes. After centrifuging, 
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the supernatant was taken out, dried by nitrogen gas, and the 
residue was reconstituted in 100 µL methanol. Following 
further centrifugation at 12,000 rpm for 10 minutes, 20 µL 
of sample solution was injected into the HPLC system. 
Peak concentration and time to reach peak concentration 
were determined directly from the plasma concentration–
time curves. Area under the curve was calculated by the 
  trapezoidal method from zero to the final sampling time.
Statistics
All experiments in this study were performed at least three 
times and results expressed as mean ± standard deviation. 
Statistical significance was assessed by Student’s t-test or 
Dunnett’s test for multiple comparisons with P , 0.05 as the 
minimal level of significance. Pharmacokinetic analysis was 
performed using Kinetica software program (v4.4; Thermo 
Fisher Scientific, Waltham, MA).
Results and discussion
Solubility study
In order to study the role of complexes in promoting the 
solubility of daidzein, a solubility experiment was designed. As 
shown in Table 1, daidzein is not only poorly soluble in water 
(3.84 µg/mL) and 2% PVA aqueous solution (9.75 µg/mL), 
but also insoluble in the majority of organic solvents that are 
commonly used in preparation of nanoparticles, eg, methylene 
chloride (1.49 µg/mL) and chloroform (0.44 µg/mL). 
  Interestingly, solubility of daidzein-phospholipid complexes 
in dichloromethane increased significantly, ie, 96 times 
(828.74 µg/mL) higher than its prototype. Similarly, solubility 
of daidzein-cyclodextrin inclusion complexes increased 95-fold 
to 757.92 µg/mL in 2% PVA compared to its prototype.
Technically, for a drug to be encapsulated in PLGA 
nanoparticles, it must be either lipophilic and combine with 
PLGA molecular chains by a single o/w method or hydro-
philic and be encapsulated in an internal aqueous phase of 
nanoparticles by a double water-in-oil-in-water (w/o/w) 
emulsification method. Therefore, this must be the main 
factor limiting daidzein formulation development, which 
strongly suggests that it is possible to encapsulate daidzein 
in PLGA nanoparticles if the solubility is changed.
In the present study, to increase lipid or aqueous solubility 
of daidzein, two different kinds of complexes using phospho-
lipid or cyclodextrin were prepared. Then, nanoparticle formu-
lations of these complexes were prepared by different methods 
due to their different solubility characteristics. Daidzein-
phospholipid complexes as lipophilic substances were easily 
encapsulated into PLGA nanoparticles by a single o/w method 
and daidzein-cyclodextrin inclusion complexes as hydrophilic 
substances were encapsulated in an internal aqueous phase of 
PLGA nanoparticles by a double w/o/w method.
Optimization of the preparation method
As shown in Figure 1, the most important step was modifying 
the drug before it was encapsulated into the nanoparticles. In the 
schematic diagram of D-PNPs (Figure 1A), daidzein was first 
combined with phospholipid to form daidzein-phospholipid 
complexes and then totally codissolved in dichloromethane with 
PLGA. In the next ultrasound step, the daidzein-phospholipid 
complexes were fixed inside the PLGA lipophilic chain side 
while the oil phase formed droplets in water. This was the key 
step in the preparation of D-PNPs formation. Dichloromethane 
evaporation maintained the shape of the D-PNPs and created 
particles that could not fuse to one another.
Compared to D-PNPs, the schematic for preparation of 
D-CNPs (Figure 1B) is more complicated. After the prepa-
ration of the daidzein-cyclodextrin inclusion complexes, a 
single emulsion was formed by high-speed mixing of the 
internal aqueous phase containing daidzein-cyclodextrin 
inclusion complexes and the organic phase containing PLGA 
and phosphatidylcholine. A stable w/o single emulsion was 
the key step in forming D-CNPs as the structure kept daidzein 
inside the PLGA layer. A w/o/w double emulsion was pre-
pared after the single emulsion was obtained, and chloroform 
was evaporated to yield D-CNPs.
As a safe drug delivery system, PLGA nanoparticles have 
been used for hundreds of drugs in modern pharmaceutical 
research, but never for daidzein. Many traditional 
Table 1 Solubility of pure daidzein and daidzein in each complex form in different solvents
Solvent Daidzein (μg/mL) Daidzein-phospholipid  
complex (μg/mL)
Daidzein-cyclodextrin inclusion   
complex (μg/mL)
h2O 3.84 ± 0.13 – 734.65 ± 15.91
2% PVA 9.75 ± 0.37 – 757.92 ± 18.78
Ch2Cl2 1.49 ± 0.08 828.74 ± 16.13 –
ChCl3 0.44 ± 0.03 697.30 ± 13.47 –
Note: Mean ± standard deviation, n = 3.
Abbreviations: Ch2Cl2, dichloromethane; ChCl3, chloroform; h2O, water; PVA, polyvinyl alcohol.
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nanotechnical methods have been used previously in the 
authors’ lab for encapsulating daidzein directly into PLGA 
nanoparticles, including the precipitation method,25,26 thin-film 
rehydration method,27,28 and emulsification-solvent evaporation 
method.29,30 The nanoprecipitation technique for preparation 
of nanoparticles is based on the interfacial deposition of 
a polymer following displacement of a semipolar solvent 
miscible with water from a lipophilic solution. However, 
this method suffers the drawback of poor incorporation 
efficiency of poor lipophilic drugs due to rapid migration and, 
therefore, loss of drug into the aqueous phase. Compared to 
the nanoprecipitation method, thin film hydration technique 
for preparation of nanoparticles is suitable for lipid-soluble 
drugs, which poses a significant challenge to encapsulating 
poor lipophilic drugs directly into water-insoluble polymers 
efficiently. The emulsification-solvent evaporation method 
also is another commonly used method for preparation of 
nanoparticles.30 However, one of the disadvantages of the 
traditional emulsification-solvent evaporation method is low 
encapsulation efficiencies of poor lipophilic drugs (for o/w 
emulsification method) or low encapsulation efficiencies of 
poor hydrophilic drugs (for w/o/w emulsification method). 
For o/w emulsification method, the drug would diffuse out 
or partition from the dispersed oil phase into the aqueous 
continuous phase and microcrystalline fragments of the 
hydrophilic drugs get deposited on the nanoparticle surface. 
This would result in low trapping of poor lipophilic drugs. 
The o/w emulsification process is therefore widely used to 
encapsulate lipid-soluble drugs. For w/o/w emulsification 
method, poor hydrophilic drugs would diffuse out or partition 
from the dispersed internal aqueous phase into the oil phase 
and this would result in low trapping of poor hydrophilic 
drugs. These traditional methods were compared to the ones 
created in this study, and the results are shown in Figure 2. 
Unfortunately, the results show that encapsulation efficiency 
and drug loading of nanoparticles obtained from traditional 
methods were very low (encapsulation efficiency ,25% 
and drug loading ,0.5%). Surprisingly, both D-PNPs and 
D-CNPs exhibited better encapsulation efficiency and 
drug loading (encapsulation efficiency .80% and drug 
loading .1% for both; D-CNPs drug loading was much 
higher than D-PNPs).
These results confirm the assumption that increased affinity 
of daidzein to the organic phase or aqueous phase increases 
the amount of drug in PLGA or reduces the loss of drug in the 
external aqueous phase during the emulsification step. In the 
traditional methods mentioned above, the majority of daidzein 
cannot encapsulate into PLGA nanoparticles directly because 
daidzein cannot coexist in the organic phase (dichloromethane) 
with PLGA or in the internal aqueous phase with 2% PVA. 
Thus, daidzein did not appear to be suitable for encapsulation in 
PLGA nanoparticles directly using traditional methods. After 
formation of phospholipid complexes or cyclodextrin inclusion 
complexes, daidzein accumulated in either the organic phase or 
internal aqueous phase to substantially improve drug loading 
and encapsulation efficiency.
Overall, daidzein PLGA nanoparticles made by any other 
method were inferior to D-PNPs and D-CNPs described here 
(D-PNPs appear inferior to D-CNPs), and these improve-
ments are due to the increased solubility of daidzein following 
complex formations.
Characterization of D-PNPs and D-CNPs
Preliminary studies were undertaken to determine the range 
of conditions (particle size and encapsulation efficiency) 
suitable for the formation of nanoparticles. As a first step, the 
present work more intensively investigated the possibility of 
forming nanoparticles with different Mw and concentration 
of PLGA in the organic phase. PLGA Mw and concentra-
tion had a great impact on size and encapsulation efficiency 
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of nanoparticles. When PLGA Mw increased from 5000 Da 
to 15,000 Da, size and encapsulation efficiency of particles 
both increased significantly (data not shown). Similarly, the 
size and encapsulation efficiency of nanoparticles increased 
as the concentration of PLGA increased (from 20 mg/mL 
to 40 mg/mL). When concentration of PLGA in the organic 
phase increased from 30 mg/mL to 40 mg/mL, the size 
of nanoparticles increased significantly and there were no 
significant differences in encapsulation efficiency (data not 
shown). This finding is in agreement with other published 
studies.31,32 Taking particle size and drug encapsulation both 
as evaluation standards, PLGA with Mw of 15,000 Da and 
concentration of 30 mg/mL were selected.
Another aspect worth noting is the function of PVA dur-
ing the preparation process. It was found that nanoparticles 
containing PVA exhibited higher encapsulation efficiency 
and small size compared to others. Some studies have also 
indicated that it was used as an emulsifier in the preparation 
of nanoparticles.33 The present research proposes PVA at 
1% (w/v) in the aqueous phase as an emulsifier during the 
preparation process of D-PNPs and D-CNPs, as it was easier 
to collect nanoparticles at this concentration than at 2% (w/v). 
The reason for PVA’s superior performance may be that it was 
easier to form a thin film on the particle surfaces, which could 
control particle size and prevent daidzein leakage. In addition, 
as described in Figure 1, the stability of w/o single emulsion 
stability is a prerequisite of successful nanoparticle prepara-
tion. It was found that dissolved daidzein-cyclodextrin inclu-
sion complexes in the high viscosity of PVA solution at 2% 
(w/v) as the internal aqueous phase increased encapsulation 
efficiency compared to the group without PVA. Regarding 
the effect of phosphatidylcholine in the D-CNPs preparation 
process, it was found that a stable single emulsion could be 
more easily formed to increase encapsulation efficiency of 
daidzein in nanoparticles in the presence of an emulsifier 
(phosphatidylcholine at 10% of PLGA weight).
After the nanoparticles were isolated, a series of detec-
tion experiments were conducted to demonstrate whether 
the structure and function of nanoparticles were consistent 
with expectations. Nanoparticle morphology, particle size, 
surface charge, and physical state of encapsulated drug were 
studied.
D-PNPs and D-CNPs yielded particles 323.2 ± 4.8 nm 
and 309.2 ± 14 nm in size (mean diameter), respectively, and 
zeta potential of D-PNPs and D-CNPs was −32.14 ± 2.53 mV 
and −18.73 ± 1.68 mV , respectively. Zeta potential is a func-
tion of the surface charge of particle dispersions which is com-
monly used to predict and control dispersion stability. Higher 
negative values were obtained for D-PNPs (−32.14 ± 2.53 mV) 
and a marked decrease in the surface charge for D-CNPs 
occurred (−18.73 ± 1.68 mV). It was speculated that the zeta 
potential of nanoparticles may be affected by the presence of 
cyclodextrins, but this theory was not explored in depth.
Encapsulation efficiency of daidzein in D-PNPs was 
81.9% ± 5% and 83.2% ± 7.2% in D-CNPs. Drug load-
ing of D-PNPs and D-CNPs was 1.27% ± 0.33% and 
1.75% ± 0.24%, respectively, indicating that D-CNPs were 
more efficient for drug loading than D-PNPs.
The morphological characterization of the optimized 
D-PNPs and D-CNPs was examined by SEM. SEM is 
expected to provide information on nanoparticle morphol-
ogy and size. Examination of SEM photographs of the 
nanoparticles revealed that the surfaces were smooth and 
spherical (Figure 3).
The physicochemical state of nanoparticles was valued 
by differential scanning calorimetry. Figure 4 shows the 
differential scanning calorimetric thermograms of daidzein, 
blank-CNPs, blank-PNPs, D-CNPs, and D-PNPs. The melt-
ing peak of daidzein appeared at 331°C (Figure 4A). The 
curves of D-CNPs and D-PNPs showed the same endothermic 
trend as blank-CNPs and blank-PNPs (Figure 4B and C), but 
did not show the daidzein melting peak (Figure 4D and E). 
Figure  3  Scanning  electron  microscopic  photographs  of  daidzein-loaded  phospholipid  complexes  poly(lactic-co-glycolic)  acid  nanoparticles  (A)  and  daidzein-loaded 
cyclodextrin inclusion complexes poly(lactic-co-glycolic) acid nanoparticles (B). 
Note: Bar represents 1 µm (80,000× magnification).
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This result indicates that daidzein was not in a crystalline 
state but in an amorphous state in nanoparticles.
Taking into account that the primary goal of this work was 
to design a nanoparticulate drug delivery system intended for 
oral administration, a critical study of these particles would be 
the evaluation of their stability in the different media present 
in the gastrointestinal tract. PLGA nanoparticle stability in 
simulated gastrointestinal conditions can be reviewed in the 
  literature. Previous research reported that PLGA nanopar-
ticles were stable in gastric fluid (pH 1.2) and intestinal fluid 
(pH 7.5).34,35 Therefore, it was speculated that both D-CNPs and 
D-PNPs were stable in simulated gastrointestinal conditions.
In vitro release
The in vitro release behavior of the nanoparticles is summa-
rized in the cumulative percentage release shown in   Figure 5. 
The accumulative pure daidzein release rate was only 26.94% 
while D-PNPs and D-CNPs achieved 80.85% and 90.12%, 
respectively, in 72 hours. It was demonstrated that pure 
daidzein cannot be released effectively from the dialysis bag, 
even when the release solution was an efficient sink. This 
may be because most of the daidzein was attached to the 
dialysis bag wall or sank to the bag bottom. This explains why 
the bioavailability of prototype daidzein is low. A possible 
reason for this was that 1 mg pure daidzein was suspended 
in 2 mL of release solution in the dialysis bag, and small 
clumps of daidzein could have blocked the dialysis bag pores 
and kept other daidzein molecules from passing through. On 
the contrary, D-PNPs and D-CNPs were released completely. 
Each release pattern fitted the Weibull equation:
  ForD-PNPS: (. )
. .
ye
t =− =
− 10 998
0 387 2 0 928
R
  ForD-CNPSR :( .) .
. .
ye
t =− =
− 10 993
03 32 0 829
There was no significant burst effect in the initial release 
phase, possibly because the washing process removed all daid-
zein adhered on the nanoparticle surface. The initial burst release 
is one of the major problems in the development of controlled 
release formulations, including drug-loaded microparticles and 
nanoparticles, especially with low Mw drugs. In the present 
experiment, both D-PNPs and D-CNPs released stably from 
the beginning and didn’t have a burst release, which is shown 
by their fit to the Weibull equation and illustrates the advan-
tageous structure of D-PNPs and D-CNPs. In both D-PNPs 
and D-CNPs, daidzein was encapsulated within PLGA. PVA 
outside the D-PNPs is an important hydrophilic layer to keep 
daidzein away from the particle surface, while the three-tier 
w/o/w double emulsion structure in D-CNPs fixed daidzein in 
the inner core of the particle.36 When nanoparticles were put in 
a release solution, PVA was dissolved and the carriers (PLGA 
or phosphatidylcholine) were dissolved gradually to form holes 
or disintegrated to release the drugs.37 This steady release rate 
from nanoparticles will allow better drug control in vivo.
Bioavailability studies
D-PNPs, D-CNPs, and daidzein suspension were orally 
administrated to male Sprague Dawley rats. Plasma 
  concentration–time curves are shown in Figure 6. A   remarkable 
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Figure 4 Differential scanning calorimetry curves of daidzein (A), blank phospholipid 
complexes  poly(lactic-co-glycolic)  acid  nanoparticles  (B),  blank  cyclodextrin 
inclusion complexes poly(lactic-co-glycolic) acid nanoparticles (C), daidzein-loaded 
phospholipid complexes poly(lactic-co-glycolic) acid nanoparticles (D), and daidzein-
loaded cyclodextrin inclusion complexes poly(lactic-co-glycolic) acid nanoparticles (E).
Abbreviation: DSC, differential scanning calorimetry.
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Figure 5 In vitro cumulate release of pure daidzein and daidzein from daidzein-
loaded  phospholipid  complexes  poly(lactic-co-glycolic)  acid  nanoparticles  and 
daidzein-loaded  cyclodextrin  inclusion  complexes  poly(lactic-co-glycolic)  acid 
nanoparticles in phosphate buffer solution (ph 7.4) at a temperature of 37°C and a 
rate of 100 rpm.
Abbreviations:  D-PNPs,  daidzein-loaded  phospholipid  complexes  poly(lactic-
co-glycolic)  acid  nanoparticles;  D-CNPs,  daidzein-loaded  cyclodextrin  inclusion 
complexes poly(lactic-co-glycolic) acid nanoparticles; h, hours.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
566
Ma et alInternational Journal of Nanomedicine 2012:7
increase in plasma concentrations and a much slower release 
of daidzein were observed when nanoparticle groups were 
studied compared to control group. This result clearly shows 
that there was a great difference in bioavailability between the 
two kinds of nanoparticles and daidzein alone. The profile of 
the D-CNPs curve can be divided in two parts: in the first part, 
D-CNPs had a high sharp absorption peak at 2 hours; in the 
second part D-CNPs had a low absorption peak at 12 hours.
Table 2 shows the pharmacokinetic parameters (peak 
concentration, time to reach peak concentration, area under 
the curve0–48, half-life, and relative bioavailability) of daidzein 
after oral administration. As shown in Table 2, peak con-
centration was found to be significantly higher for D-PNPs 
(1.92 ± 0.69 µg/mL) and D-CNPs (2.44 ± 0.74 µg/mL) 
than for daidzein suspension group (1.35 ± 0.47 µg/mL). 
  Similarly, half-life was faster for D-PNPs (8.62 ± 2.69 hours) 
and D-CNPs (3.38 ± 1.24 hours) compared to daidzein 
  suspension group (1.15 ± 0.55 hours) and time to reach peak 
concentration was also faster for D-PNPs (5.97 ± 2.17 hours) 
and D-CNPs (2.04 ± 0.91 hours) compared to daidzein sus-
pension group (0.76 ± 0.21 hours). In the same way, area 
under the curve0–48 for D-PNPs (10.63 ± 3.77 h µg/mL) and 
D-CNPs (16.90 ± 6.93 h µg/mL) was five- and eight-fold 
higher than that of daidzein suspension (1.91 ± 0.81 h µg/mL). 
Finally, relative bioavailability of D-PNPs and D-CNPs was 
calculated to be 556.98% and 885.62%, respectively, com-
pared to daidzein suspension group. These results verify that 
both D-PNPs and D-CNPs were effective in improving the 
oral bioavailability of daidzein.
The pharmacokinetic parameters clearly demonstrate 
that the two kinds of nanoparticles studied greatly improved 
bioavailability for daidzein. The reasons are many, but 
among the most salient is the nano-based drug delivery 
system. On the one hand, particles that are nanoscale in 
size are easily absorbed into the folds of the intestinal wall, 
while large particle surface area to volume lends itself to 
rapid drug dissolution.38–40 On the other hand, particulate 
systems for oral delivery can protect the drug at low pH 
levels, facilitate absorption into the intestinal tract, and 
bypass unwanted metabolic degradation, and the nature of 
degradation of the carrier maintains a sustained release.41,42 
Amorphous dispersion of daidzein in nanoparticles might 
be another reason for better absorption.43,44 Apart from 
these reasons, more importantly, daidzein complexes 
may play an important role in absorption. Some studies 
have demonstrated that phospholipid-drug complexes 
and cyclodextrin-drug complexes could increase oral 
bioavailability by improving the liposolubility and solubility 
of drugs.21,22 Furthermore, studies have also pointed out 
that daidzein as a hydrophilic compound could transport 
across the intestinal barrier via the paracellular pathway 
and passive transport is the only mechanism of daidzein 
absorption in the small intestine of rats, at least within the 
concentrations tested.45 In addition, phospholipids have 
been proven to have a high affinity for flavonoids and 
accelerates daidzein transport across the cell membrane.46–48 
Cyclodextrin has been proven as a drug absorption enhancer 
as well.49,50 Since daidzein is a typical poor hydrophilic and 
poor lipophilic drug with very low oral bioavailability,7 
the greatly improved liposolubility and solubility of 
daidzein by D-PNPs and D-CNPs should be favorable 
to its absorption in the gastrointestinal tract. Daidzein 
complex intermediated not only the increased drug loading 
of nanoparticles, but also promoted drug absorption 
in vivo.
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Figure 6 Mean plasma concentration–time profiles of daidzein in rats after oral 
administration  of  daidzein-loaded  phospholipid  complexes  poly(lactic-co-glycolic) 
acid nanoparticles, daidzein-loaded cyclodextrin inclusion complexes poly(lactic-co-
glycolic) acid nanoparticles, and daidzein suspension at a dose of 10 mg/kg (n = 3).
Abbreviations:  conc,  concentration;  D-PNPs,  daidzein-loaded  phospholipid 
complexes  poly(lactic-co-glycolic)  acid  nanoparticles;  D-CNPs,  daidzein-loaded 
cyclodextrin  inclusion  complexes  poly(lactic-co-glycolic)  acid  nanoparticles; 
h, hours.
Table 2 Pharmacokinetic parameters of daidzein after oral adminis-
tration  of  daidzein-loaded  phospholipid  complexes  poly(lactic-co-
glycolic) acid nanoparticles, daidzein-loaded cyclodextrin inclusion 
complexes poly(lactic-co-glycolic) acid nanoparticles, and daidzein 
suspension at the dose of 10 mg/kg
Parameters Daidzein  
suspension
D-PNPs D-CNPs
Cmax (µg/mL) 1.35 ± 0.47 1.92 ± 0.69 2.44 ± 0.74a
AUC0–48 (h µg/mL) 1.91 ± 0.81 10.63 ± 3.77a 16.90 ± 6.93b
T1/2 (hours) 1.15 ± 0.55 8.62 ± 2.69a 3.38 ± 1.24a
Tmax (hours) 0.76 ± 0.21 5.97 ± 2.1b 2.04 ± 0.91a
Frel (%) – 556.98 885.62
Notes: aP , 0.05 compared with daidzein suspension group; bP , 0.01 compared 
with daidzein suspension group. Mean ± standard deviation, n = 3.
Abbreviations: AUC, area under the curve; Cmax, peak concentration; D-CNPs, 
daidzein-loaded  cyclodextrin  inclusion  complexes  poly(lactic-co-glycolic)  acid 
nanoparticles;  D-PNPs,  daidzein-loaded  phospholipid  complexes  poly(lactic-
co-glycolic)  acid  nanoparticles;  Frel,  relative  bioavailability;  Tmax,  time  to  peak 
concentration; T1/2, half-life.
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Somewhat surprisingly, the in vivo bioavailability study 
of D-PNPs and D-CNPs in the present study showed that 
the absorption curves were different shapes. D-PNPs had 
an absorption peak at about 6 hours, while D-CNPs had a 
high sharp absorption peak at 2 hours and a low absorption 
peak at 12 hours. It is generally believed that the ileum and 
colon are the main absorption sites for nanoparticles; as 
daidzein-phospholipid complexes in D-PNPs are lipophilic 
substances, and because of their small size, they would be 
easily taken up by epithelial cells in the ileum and colon 
as whole nanoparticles or as drug released from PLGA 
nanoparticles.51,52 The absorption process may continue for 
8–10 hours with a coincident absorption peak. However, a 
completely different situation may exist for D-CNPs. As 
far as is known, daidzein-cyclodextrin inclusion complexes 
are not likely to be absorbed directly by intestinal epithelial 
cells, but as hydrophilic compounds they will easily leak out 
of the nanoparticles into gastric juice. By using cyclodex-
trin as an absorption enhancer, daidzein would be absorbed 
easily in the small intestine. The first absorption peak may 
be due to this process. The second peak that appeared after 
10 hours was lower and wider, suggesting that daidzein was 
absorbed into the blood slowly. Based on previous reports 
and the concentration–time curve of pure daidzein, the sec-
ond peak was not caused by entry into hepatic circulation 
as this did not happen in the prototype daidzein absorption 
curve. As cyclodextrin cannot pass through intestinal epithe-
lial cells, the most likely explanation was that D-CNPs or 
daidzein-cyclodextrin inclusion complexes were taken up by 
lymphocytes in the small intestine and daidzein eventually 
entered the blood after being transported in microfold cells 
through the ileum.14,53,54
Conclusion
In the present study, an effective strategy for enhancing the 
oral absorption of daidzein, which has poor hydrophilicity 
and poor lipophilicity, was developed. Daidzein was 
incorporated into PLGA nanoparticles by two improved 
methods. Both of them used daidzein complexes as 
intermediates that increased the solubility of daidzein to 
either aqueous or organic solvents. The soluble complexes 
were successfully used to form PLGA nanoparticles under 
optimal preparation conditions. In this experiment, D-PNPs 
were prepared by an emulsion evaporation method using 
daidzein-phospholipid complexes as an intermediate, 
while D-CNPs were prepared by a double emulsion 
method using daidzein-cyclodextrin inclusion complexes 
as an intermediate. Detection of nanoparticle properties 
showed that both structures were   consistent with theoretical 
assumptions. More importantly, the pharmacokinetic results 
showed that both of them improved oral bioavailability of 
daidzein in rats. These formulations overcome the problem 
of poor daidzein encapsulation in the lipophilic polymer 
carrier PLGA. Two distinct compound-nanoparticles were 
produced from the same drug by producing and using two 
different complexes as intermediates. This is a new approach 
for the formulation of drugs with both poor lipophilic and 
poor hydrophilic properties.
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